E-POSTER PRESENTATION SCHEDULE

Rev. 09/09/2025

12th September - h. 18:00-18:50

	CHAIRS: Sébastien Lacroix-Desmazes (France)	Peter Lenting (France)	Cecile Denis (France)	David Lillicrap (Canada)
	PETRARCA	CORNARO	GIOTTO	GALILEO
18:00	PO-02 Intronic variants in mild haemophilia A map to newly identified F8 endothelial enhancers D. Jones (UK)	PO-16 Inhibitors status of paediatric patients with haemophilia A treated with emicizumab in Greek children A. Dettoraki (Greece)	PO-24 Diagnostic accuracy of the total thrombus-formation analysis system (T-TAS) for platelet function disorders: a comprehensive evaluation C. Gran (Sweden)	PO-37 Safety of immunosuppressive therapy in acquired haemophilia A N. Roberts (UK)
18:10	PO-19 Perioperative management with efanesoctocog alfa in patients with haemophilia A in the XTEND clinical trial programme: a European subanalysis P. Chowdary (UK)	PO-15 Relevance of FVIII-immune complex properties in the induction of immune tolerance in hemophilia A S. Delignat (France)	PO-14 Thrombin generation profiling in rare coagulation factor deficiencies: associations with bleeding severity and potential for screening B. Haisma (The Netherlands)	PO-01 Human factor VIII transgenic mice as a model of acquired hemophilia A L. Dourthe (France)
18:20	PO-18 Single-cell RNA sequencing of peripheral blood reveals immune dysregulation and severity-associated gene signature in children with hemophilia A F. Makrufardi (Indonesia)	PO-31 F8 genotype and immune tolerance induction outcome in people with hemophilia A and inhibitors: a systematic review and metanalysis R. Camelo (Brazil)	PO-36 Compatibility and stability of reconstituted fibrinogen concentrate (CLOTTAFACT® / FibCLOT®) with CODAN infusion set C. Krier (France)	PO-23 Real-world effectiveness and usage of recombinant factor IX Fc (rFIXFc) in haemophilia B by age groups: final B-MORE study data E. Zapotocka (Czech Republic)
18:30	PO-27 Impact of recombinant FVIII modifications on platelet binding and phenotype shift in haemophilia A A. Strebel (Switzerland)	PO-34 Prophylaxis for inherited factor X deficiency: a systematic review R. Camelo (Brazil)	PO-04 Structural analysis of coagulation factor VIII bound to anti-A2 domain antibody inhibitors indicate an antigenic hotspot epitope and novel inhibition mechanism P. Spiegel (USA)	PO-21 Cost effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe or moderately severe hemophilia B in Sweden S. Johansson (Sweden)
18:40	PO-20 Assessing emicizumab levels in hemophilia A: impact of different coagulation assays in clinical samples C. Gran (Sweden)	PO-17 Cell therapy for thrombotic microangiopathies P. Trionfini (Italy)		

13th September - h. 17:45-18:45

CHAIRS:	Sébastien Lacroix-Desmazes (France)	Peter Lenting (France)	Cecile Denis (France)	David Lillicrap (Canada)
	PETRARCA	CORNARO	GIOTTO	GALILEO
17:45	PO-22 Investigating the novel role of factor VIII in maintaining endothelial cell function and extracellular matrix protein expression A. Follenzi (Italy)	PO-08 The gene conversions involving Pro1266 contribute to different von Willebrand disease types L. Baronciani (Italy)	PO-09 Induced pluripotent stem cells (iPSC)-derived endothelial cells to study complement activation and thrombus formation in aHUS S. Gastoldi (Italy)	PO-29 Evaluation of prophylactic treatment outcomes in children with severe haemophilia A in a resource-limited setting: a cross-sectional study in Somalia D. Mohamed (India)
17:55	PO-13 Bleed Treatment Outcomes from the XTEND-ed study in patients aged 50 years and older P. Chowdary (UK)	PO-35 Bleeding events in von Willebrand disease type 1 yearly treatable with desmopressin A. Gringeri (Italy)	PO-03 Recombinant ADAMTS13 Prophylaxis for the treatment of pediatric patients with congenital thrombotic thrombocytopenic purpura: pooled outcomes from two phase 3 studies P. Zhang (USA)	PO-11 FVIII promotes in vitro osteoblast differentiation independently from the coagulation cascade C. Borsotti (Italy)
18:05	PO-12 Joint replacement/revision surgery outcomes with efanesoctocog alfa: 4 years' experience in the XTEND Clinical Programme R. Klamroth (Germany)	PO-07 Calcium allosterically inhibits VWF binding to GPIbα in the physiological blood concentration range A. Tischer (USA)	PO-05 Gender differences in clinical manifestations and severity of FVII deficiency: Insights from the PRO-RBDD and EN-RBD databases S. Mohsenian (Italy)	PO-32 Chronic pain, its perception and management, in men and women with hemophilia: preliminary data S. Pasca (Italy)
18:15	PO-10 Modulating the electrostatic potential of coagulation factor VIII can improve its therapeutic profile S. Lacroix-Desmazes (France)	PO-06 Physiological concentrations of calcium alter the quaternary structure of VWF A1A2A3 domains M. Auton (USA)	PO-33 Perception of erectile dysfunction in adults with hemophilia R. Camelo (Brazil)	PO-26 ATLAS-NEO: A Phase 3, one-way crossover study evaluating the fitusiran antithrombin-based dose regimen (AT-DR) in males aged ≥12 years with severe haemophilia A or B, with or without inhibitors Salim Kichou (USA)
18:25	PO-38 The new locally designed method for schistocyte estimation on the DI-60 digital morphology analyser – a step forward from standard light microscopy? M. Milos (Croatia)	PO-30 Beyond bleeding: sexual function and anxiety in women with hereditary bleeding disorders B. Koc (Turkey)	PO-40 Impact of pharmacokinetics guided individualized prophylaxis on clinical outcomes in children with hemophilia A R. Camelo (Brazil)	PO-25 Phase 3 study investigating the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to <12 years with haemophilia A/B, with or without inhibitors: ATLAS-KIDS, a trial in progress M. Demissie (USA)
18:35	POSSIBLE REPEAT TIME	POSSIBLE REPEAT TIME	POSSIBLE REPEAT TIME	POSSIBLE REPEAT TIME